Björn Dahlbäck (born 1949) is a Swedish physician, medical researcher, and professor of clinical chemistry, specializing in hematology and the molecular mechanisms of blood coagulation.[1] He determined that activated protein C (APC) resistance is the most common inherited risk factor of venous thrombosis.
Education and career
Dahlbäck graduated with an M.D. from Lund University and then completed his medical internship and residency at Malmö's University Hospital,[2] which is now merged into Skåne University Hospital. In 1981 he received from Lund University his doctorate with dissertation The activation of prothrombin on the platelet surface[3] under the supervision of Johan Stenflo. Dahlbäck was a postdoc at La Jolla's Scripps Research, where his supervisor was Hans J. Müller-Eberhard, and later was a visiting scholar at Oklahoma Medical Research Foundation (OMRF). In 1989 at Lund University, Dahlbäck was appointed a full professor of clinical chemistry, specializing in hematology and cardiac and cardiovascular systems.[2][1] He is also the director of the blood coagulation unit at Malmö General Hospital.[4]
His research was important in showing that APC resistance is caused by a harmful mutation in the F5 gene corresponding to the protein Factor V; the specific mutation was subsequently identified by several groups of researchers and is now called Factor V Leiden.[2] In 2013, Dahlbäck and colleagues identified the F5 gene mutation that causes the phenotype called "east Texas bleeding disorder".[5][2]
In 2000, Academic Press published Hematology: Landmark Papers of the Twentieth Century , which included the 1994 paper Resistance to activated protein C as a basis for venous thrombosis by Peter J. Svensson and Björn Dahlbäck.[8][9]
Dahlbäck, Björn (1991). "Protein S and C4b-Binding Protein: Components Involved in the Regulation of the Protein C Anticoagulant System". Thrombosis and Haemostasis. 66 (1): 049–061. doi:10.1055/s-0038-1646373. PMID1833851. S2CID24929072.
Zöller, B.; Dahlbäck, B. (1994). "Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis". The Lancet. 343 (8912): 1536–1538. doi:10.1016/S0140-6736(94)92940-8. PMID7911873. S2CID34764295.
Dahlbäck, Björn (1995). "The protein C anticoagulant system: Inherited defects as basis for venous thrombosis". Thrombosis Research. 77 (1): 1–43. doi:10.1016/0049-3848(94)00138-4. PMID7701473.
Lane, David A.; Mannucci, Pier M.; Bauer, Kenneth A.; Bertina, Rogier M.; Bochkov, Nikolay P.; Boulyjenkov, Victor; Chandy, Mammen; Dahlbäck, Björn; Ginter, E. K.; Miletich, Joseph P.; Rosendaal, Frits R.; Seligsohn, Uri (1996). "Inherited Thrombophilia*: Part 2". Thrombosis and Haemostasis. 76 (6): 0824–0834. doi:10.1055/s-0038-1650673. S2CID15544852.
Lindqvist, P.; Dahlbäck, B.; Marŝál, K. (1999). "Thrombotic risk during pregnancy: A population study". Obstetrics & Gynecology. 94 (4): 595–599. doi:10.1016/S0029-7844(99)00308-7. PMID10511366.
Blom, Anna M.; Villoutreix, Bruno O.; Dahlbäck, Björn (2004). "Complement inhibitor C4b-binding protein—friend or foe in the innate immune system?". Molecular Immunology. 40 (18): 1333–1346. doi:10.1016/j.molimm.2003.12.002. PMID15072852.
